AU2017319512A1 - Use of CGRP receptor antagonists in neuroprotection and neurological disorders - Google Patents

Use of CGRP receptor antagonists in neuroprotection and neurological disorders Download PDF

Info

Publication number
AU2017319512A1
AU2017319512A1 AU2017319512A AU2017319512A AU2017319512A1 AU 2017319512 A1 AU2017319512 A1 AU 2017319512A1 AU 2017319512 A AU2017319512 A AU 2017319512A AU 2017319512 A AU2017319512 A AU 2017319512A AU 2017319512 A1 AU2017319512 A1 AU 2017319512A1
Authority
AU
Australia
Prior art keywords
leu
ala
arg
thr
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017319512A
Other languages
English (en)
Other versions
AU2017319512A2 (en
Inventor
Christopher J. Soares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2017319512A1 publication Critical patent/AU2017319512A1/en
Publication of AU2017319512A2 publication Critical patent/AU2017319512A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
AU2017319512A 2016-09-02 2017-08-30 Use of CGRP receptor antagonists in neuroprotection and neurological disorders Abandoned AU2017319512A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383334P 2016-09-02 2016-09-02
US62/383,334 2016-09-02
PCT/US2017/049460 WO2018045083A1 (en) 2016-09-02 2017-08-30 Use of cgrp receptor antagonists in neuroprotection and neurological disorders

Publications (2)

Publication Number Publication Date
AU2017319512A1 true AU2017319512A1 (en) 2019-03-21
AU2017319512A2 AU2017319512A2 (en) 2019-07-11

Family

ID=59914517

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017319512A Abandoned AU2017319512A1 (en) 2016-09-02 2017-08-30 Use of CGRP receptor antagonists in neuroprotection and neurological disorders

Country Status (10)

Country Link
US (2) US11390654B2 (https=)
EP (2) EP4316595A3 (https=)
JP (2) JP7123932B2 (https=)
KR (1) KR102657418B1 (https=)
CN (1) CN109922820A (https=)
AU (1) AU2017319512A1 (https=)
CA (1) CA3035561A1 (https=)
ES (1) ES2965087T3 (https=)
IL (1) IL265099B2 (https=)
WO (1) WO2018045083A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4316595A3 (en) 2016-09-02 2024-04-17 Christopher J. Soares Use of cgrp receptor antagonists in treating glaucoma
EP3893918B1 (en) * 2018-12-10 2024-09-25 Rigshospitalet Vasodilators for use in the treatment of a retinal ischemic disorder
CN118717761A (zh) * 2024-05-27 2024-10-01 复旦大学 瑞美吉泮在制备治疗/预防阿尔茨海默病药物中的应用
CN119524110B (zh) * 2024-12-16 2026-03-20 中国人民解放军军事科学院军事医学研究院 Cgrp在减轻植入式神经电极免疫排斥中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH657779A5 (de) 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4530838A (en) 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
JPS62231168A (ja) 1986-03-21 1987-10-09 ハイブリテツク・インコ−ポレイテツド アナライト−レセプタ−分析用内部標準を設けるための改良法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
ES2181691T5 (es) 1992-06-11 2007-10-01 Alkermes Controlled Therapeutics, Inc. Sistema de distribucion de proteina eritropoyetina.
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1994021665A1 (en) 1993-03-24 1994-09-29 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
US5698401A (en) 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
WO1997041223A1 (en) * 1996-04-15 1997-11-06 The University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
PT1248643E (pt) * 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
PT1534313E (pt) * 2002-07-30 2013-01-25 Omeros Corp Soluções e método de irrigação oftalmológica
US7812120B2 (en) 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
RU2385878C2 (ru) 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
EP1718665B1 (en) * 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2286840A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related diseases
WO2007055728A1 (en) 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
EP2258382A3 (en) 2005-03-31 2014-05-14 Amylin Pharmaceuticals, LLC Amylin and amylin agonists for treating psychiatric diseases and disorders
WO2007055743A2 (en) 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR20100098628A (ko) 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
US20150031623A1 (en) 2011-09-29 2015-01-29 Mcw Research Foundation, Inc. Thrombopoietin receptor ligands for neuroprotection
US20140249076A1 (en) 2011-10-18 2014-09-04 Astrazeneca Pharmaceuticals Lp Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
CA2861392C (en) * 2012-01-26 2021-08-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
ES2746031T3 (es) * 2012-02-27 2020-03-04 Bristol Myers Squibb Co Sal de N-(5S,6S,9R)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5H-ciclohepta[B]piridin-9-IL-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidina-1-carboxilato
WO2015176017A1 (en) * 2014-05-16 2015-11-19 Salk Institute For Biological Studies Compositions and methods for treating metabolic disorders
EP4316595A3 (en) 2016-09-02 2024-04-17 Christopher J. Soares Use of cgrp receptor antagonists in treating glaucoma

Also Published As

Publication number Publication date
EP3506925B1 (en) 2023-09-06
EP3506925C0 (en) 2023-09-06
US20230212248A1 (en) 2023-07-06
JP2022126857A (ja) 2022-08-30
KR20190044665A (ko) 2019-04-30
CA3035561A1 (en) 2018-03-08
EP4316595A3 (en) 2024-04-17
CN109922820A (zh) 2019-06-21
KR102657418B1 (ko) 2024-04-15
US20200165305A1 (en) 2020-05-28
JP7123932B2 (ja) 2022-08-23
WO2018045083A1 (en) 2018-03-08
EP4316595A2 (en) 2024-02-07
IL265099A (en) 2019-04-30
US12103951B2 (en) 2024-10-01
IL265099B2 (en) 2024-09-01
JP2019530741A (ja) 2019-10-24
EP3506925A1 (en) 2019-07-10
US11390654B2 (en) 2022-07-19
IL265099B1 (en) 2024-05-01
AU2017319512A2 (en) 2019-07-11
ES2965087T3 (es) 2024-04-10

Similar Documents

Publication Publication Date Title
US12103951B2 (en) Use of CGRP receptor antagonists in neuroprotection and neurological disorders
EP2961426B1 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
EP3352759A1 (en) Treatment of neurodegenerative diseases
US12329756B2 (en) Regulation of eIF4E activity for migraine therapy
Kodati et al. Oral administration of a dual ETA/ETB receptor antagonist promotes neuroprotection in a rodent model of glaucoma
AU2019262664B2 (en) PEDF-derived peptides for promoting meibomian gland regeneration and uses thereof
Ruan et al. Adrenoceptors in the eye–physiological and pathophysiological relevance
US10017554B2 (en) Neuropeptide Y-derived peptides
US20140315811A1 (en) Ophthalmic preparations based on pacap (pituitary adenylate cyclase activating polypeptide) which restore the normal visual function in early glaucoma
HK40008689A (en) Use of cgrp receptor antagonists in neuroprotection and neurological disorders
WO2019048854A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
Samsam et al. Role of neuropeptides in migraine: where do they stand in the latest expert recommendations in migraine treatment?
EP2061317A2 (en) Intrathecal administration of triptan compositions to treat non-migraine pain
CN121941705A (zh) 可溶性骨形态发生蛋白（bmp）受体1b型蛋白及其用途
Ferrer et al. Ophthalmic therapeutics: new basic research and clinical studies
Stucky SEX DIFFERENCES IN GENE EXPRESSION AND PAIN-RELATED BEHAVIORS IN A PRECLINICAL MODEL OF MIGRAINE
Geppetti et al. Neuropeptides and the respiratory tract: Relevance to asthma and rhinitis

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 28 MAY 2019

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted